Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN ...

Ad Hoc Announcement Pursuant to Art.?53 LR Geneva, Switzerland, July 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing ...

Draig Therapeutics, a clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric ...

Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule ...

IND authorization paves the way for initiation of GT-02287 Phase 2 clinical development in the U.S., expected during 3Q26FDA’s decision follows ...

Results point to potential to restore vision with drugs, non-invasively, reversibly, via a mechanism that is independent to ...

Merck & Co. has nixed the phase 2 study of a potential Alzheimer’s disease medicine after the drug underwhelmed in an interim analysis, marking another blow for the pharma’s struggling partner ...

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or ...

Hikma Pharma launches anti-seizure medication Xcopri in the UAE: London Tuesday, July 7, 2026, 15:00 Hrs [IST] Hikma Pharmaceuticals PLC, the multinational pharmaceutical company, ...

Neurocrine Biosciences, Inc. stays a Buy as Ingrezza, Crenessity, and Vykat drive 44% revenue growth; see valuation, patents & catalysts. Click for this NBIX stock update.

Scientists at the University of California San Diego have uncovered how genetic mutations cause a rare group of inherited neuromuscular disorders and identified promising new strategies to correct ...